Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Jenna A. Bosco"'
Autor:
Lawrence, Steinman, Edward, Fox, Hans-Peter, Hartung, Enrique, Alvarez, Peiqing, Qian, Sibyl, Wray, Derrick, Robertson, DeRen, Huang, Krzysztof, Selmaj, Daniel, Wynn, Gary, Cutter, Koby, Mok, Yanzhi, Hsu, Yihuan, Xu, Michael S, Weiss, Jenna A, Bosco, Sean A, Power, Lily, Lee, Hari P, Miskin, Bruce A C, Cree
Publikováno v:
New England Journal of Medicine. 387:704-714
The monoclonal antibody ublituximab enhances antibody-dependent cellular cytolysis and produces B-cell depletion. Ublituximab is being evaluated for the treatment of relapsing multiple sclerosis.In two identical, phase 3, double-blind, double-dummy t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf08f64d37370fec503fd270f5149587
https://doi.org/10.1056/nejmoa2201904
https://doi.org/10.1056/nejmoa2201904
Autor:
Sean A. Power, Richard Shubin, Matthew Gormley, Amy E. Lovett-Racke, Edward Fox, Sibyl Wray, Maria Petracca, Koby Mok, Yue Liu, Matilde Inglese, Jenna A. Bosco, Michael S Weiss, Sirio Cocozza
Publikováno v:
Multiple Sclerosis (Houndmills, Basingstoke, England)
Background: Ublituximab, a novel monoclonal antibody (mAb) targeting a unique epitope on the CD20 antigen, is glycoengineered for enhanced B-cell targeting through antibody-dependent cellular cytotoxicity (ADCC). Greater ADCC may allow lower doses an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3b81880946bb454b6a33982091d6eda
https://doi.org/10.1177/1352458520918375
https://doi.org/10.1177/1352458520918375